Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G. Pignochino Y, et al. Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5. Mol Cancer. 2017. PMID: 28454547 Free PMC article.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Grignani G, et al. Among authors: pignochino y. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217671 Free article. Clinical Trial.
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights.
Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E, Giordano G, Merlini A, Miglio U, Berrino E, Napione L, Isella C, Capozzi F, Basiricò M, Marsero C, Gerardi I, Venesio T, Sangiolo D, Aglietta M, D'Ambrosio L, Pignochino Y. Chiabotto G, et al. Among authors: pignochino y. Cancers (Basel). 2020 Jun 10;12(6):1519. doi: 10.3390/cancers12061519. Cancers (Basel). 2020. PMID: 32531992 Free PMC article.
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, Centomo ML, Leuci V, D'Ambrosio L, Aglietta M, Sangiolo D, Grignani G, Pignochino Y. Giordano G, et al. Among authors: pignochino y. Cells. 2021 Oct 26;10(11):2893. doi: 10.3390/cells10112893. Cells. 2021. PMID: 34831119 Free PMC article.
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study.
Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo ML, Chiabotto G, Brusco S, Basiricò M, Maldi E, Pisacane A, Leuci V, Sangiolo D, D'Ambrosio L, Aglietta M, Kasper B, Bardelli A, Grignani G. Pignochino Y, et al. Cancers (Basel). 2021 Dec 15;13(24):6295. doi: 10.3390/cancers13246295. Cancers (Basel). 2021. PMID: 34944915 Free PMC article.
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination.
Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldi E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D'Ambrosio L, Bardelli A, Pignochino Y, Grignani G. Merlini A, et al. Among authors: pignochino y. Front Oncol. 2022 Aug 30;12:844250. doi: 10.3389/fonc.2022.844250. eCollection 2022. Front Oncol. 2022. PMID: 36110934 Free PMC article.
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM. Pignochino Y, et al. BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1. BMC Cancer. 2015. PMID: 25952930 Free PMC article.
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F. Cova E, et al. Among authors: pignochino y. Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019. Int J Nanomedicine. 2019. PMID: 30774332 Free PMC article.
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D. Mesiano G, et al. Among authors: pignochino y. Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018. Oncoimmunology. 2018. PMID: 30393581 Free PMC article.
50 results